MD — Pediatrix Medical Group, Inc.

Summary of Q3 2025 Earnings Call for Pediatrix Medical Group, Inc.

1. Key Financial Results and Metrics

• Adjusted EBITDA: $87 million, exceeding expectations.
• Consolidated Revenue: Decreased by approximately $54 million due to portfolio restructuring but was offset by strong same-unit growth of 8% and pricing up 7.5%.
• Operating Cash Flow: Increased to $138 million from $96 million year-over-year, driven by higher earnings and improved cash flow from accounts receivable (AR).
• Share Repurchases: 1.2 million shares bought back in the quarter, totaling 1.7 million shares year-to-date.
• Cash Position: Ended the quarter with $340 million in cash and net debt of just over $260 million, reflecting a net leverage of under 1x based on adjusted EBITDA outlook.

2. Strategic Updates and Business Highlights

• Portfolio Restructuring: Successfully executed, leading to improved operational performance and focus on core areas such as pediatric surgery, neurology, and cardiac intensive care.
• Research and Innovation: Pediatrix maintains a significant clinical footprint with over 1,300 physicians and 1,170 advanced practice providers. They are a leader in neonatology research with 1,395 peer-reviewed publications.
• Technology Leadership: Introduction of the proprietary BabySteps system aimed at enhancing clinical decision-making and improving outcomes for high-risk NICU patients.
• Acquisition Activity: Completed an acquisition of several neonatology, MFM, and OB hospitalist practices, reinforcing their market position.

3. Forward Guidance and Outlook

• Full-Year Adjusted EBITDA Guidance: Wider range of $270 million to $290 million due to practice bonus variability.
• Seasonality: Anticipated normal seasonality in Q4 with no expected shifts, although some variability may arise from ongoing initiatives.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in consolidated revenue due to restructuring raises concerns about the impact on future growth.
• Expense Increases: General and administrative expenses rose slightly due to increased incentive compensation, which could pressure margins.
• Market Headwinds: The company acknowledged significant healthcare headwinds that could affect operations and financial performance moving forward.

5. Notable Q&A Insights

• Capital Deployment: Management is cautious but open to aggressive share repurchases and exploring internal and external growth opportunities.
• Competitive Landscape: The restructuring has not negatively impacted the company’s attractiveness to new practices; instead, it has enhanced focus and operational efficiency.
• Pricing Dynamics: Strong pricing was attributed to improved RCM collections, increased acuity, and favorable payer mix, though these factors are variable and may not sustain.
• Exchange Subsidies: Uncertainty remains regarding the impact of enhanced subsidies on exchange plans, with management hopeful for continued benefits.

Overall, Pediatrix Medical Group reported a strong quarter with solid operational metrics despite challenges from restructuring and market conditions. The company remains focused on strategic growth and innovation while navigating potential headwinds in the healthcare landscape.